Ocrelizumab Injection 300 mg Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 300 mg
Reference Brands: Ocrevus(EU & US)
Category: Multiple sclerosis
Ocrelizumab is a monoclonal antibody that targets CD20-positive B-cells, reducing inflammation and immune attack in multiple sclerosis. It decreases relapse rates, slows disease progression, and reduces lesion activity. Benefits include improved neurological function, fewer relapses, and better quality of life for MS patients, with infusions every six months.
Product Description:
Ocrelizumab, marketed as Ocrevus, is approved in the US by the FDA and in the EU via EMA for relapsing and primary progressive multiple sclerosis. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing processes, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial results and manufacturing standards, while the EMA ensures regional safety and quality compliance.
Ocrelizumab Injection — third party manufacturing & bulk supply
Ocrelizumab Injection 300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Ocrelizumab Injection is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Ocrelizumab Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Ocrelizumab Injection →Frequently Asked Questions
Ocrelizumab is used for the treatment of multiple sclerosis (MS), including relapsing forms of MS and primary progressive multiple sclerosis (PPMS). It helps slow disease progression and reduce relapses.
Ocrelizumab is a humanized monoclonal antibody that targets CD20-positive B cells, which play a key role in the immune system’s attack on nerve cells in multiple sclerosis.
The main trade name is Ocrevus.
Ocrelizumab is manufactured by Roche and marketed in the United States by Genentech, a member of the Roche Group.
The generic name is Ocrelizumab.
The brand name is Ocrevus.
Ocrelizumab is manufactured in the United States and Europe by Roche/Genentech and supplied globally under strict regulatory standards.
Related Products
Natalizumab Injection
Strength:
300 mg
Form: IV Injection
Reference Brands: Tysabri(US & EU)
View Details
Alemtuzumab Injection
Strength:
12 mg/1,2 ml
Form: Injection
Reference Brands: Lemtrada(US & EU)
View Details
Ofatumumab Injection
Strength:
20 mg/mL
Form: Injection(SQ)
Reference Brands: Kesimpta(US)
View Details
Lamotriginevdispersible Tablets
Strength:
XR: 25 mg, 50 mg, 100 mg, 200 mg; IR: 25 mg, 100 mg, 200 mg, 300 mg
Form: Tablets(IR & ER)
Reference Brands: Lamictal, Lamictal XR(EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers
